Cancer Therapy Co. Karyopharm Hits Ch. 11 With Merger Plan

By Alex Wittenberg · November 2, 2026, 12:23 PM EST

Pharmaceutical company Karyopharm Therapeutics Inc. on Monday filed for Chapter 11 protection in a Texas bankruptcy court with $441.5 million in debt and a plan to merge with biotechnology firm Ayrmid...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

Karyopharm Therapeutics Inc.

Case Number

4:26-bk-90827

Court

Texas Southern

Nature of Suit

Date Filed

November 02, 2026